Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors

Title:Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors

Volume: 16 Issue: 2

Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*

Affiliation:

• Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,China

Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.

Abstract: Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.

Cite this article as:

Shao Wei-Hua , Wang Lei-Yun and Yin Ji-Ye *, Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors, Current Pharmacogenomics and Personalized Medicine 2018; 16 (2) . https://dx.doi.org/10.2174/1875692116666180821152601